Track OPKO Health, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

OPKO Health, Inc. OPK Open OPKO Health, Inc. in new tab

1.13 USD
EPS
-0.27
P/B
0.66
ROE
-16.92
Beta
1.41
Target Price
3.76 USD
OPKO Health, Inc. logo

OPKO Health, Inc.

🧾 Earnings Recap – Q3 2025

OPKO Health's Q3 2025 results showcased strategic progress, highlighted by the successful sale of its oncology division and a focus on core clinical operations, driving a commitment to shareholder value.

  • Completed the sale of BioReference Health's oncology division for $192.5 million plus an additional $32.5 million in performance-based earn-out.
  • Achieved a 5.3% increase in testing volume at BioReference, with a 20% rise in adoption of the 4Kscore test for prostate cancer.
  • Repurchased $25.1 million in stock during 2025 to enhance shareholder returns, with $126 million remaining under the repurchase program.
  • Advanced pipeline with four therapeutics in clinical development, including promising candidates in the immuno-oncology space and a COVID-19 antibody initiative.
  • Focused on operational efficiencies and growth through new customer segments and revenue streams, maintaining a streamlined workforce at BioReference.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateJuly 30, 2026
EPS-0.27
Book Value1.67
Price to Book0.66
Debt/Equity32.95
% Insiders49.486%
Growth
Revenue Growth-0.17%
Earnings Growth-0.13%
Estimates
Forward P/E-3.44
Forward EPS-0.32
Target Mean Price3.76

DCF Valuation

Tweak assumptions to recompute fair value for OPKO Health, Inc. (OPK)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

OPKO Health, Inc. Logo OPKO Health, Inc. Analysis (OPK)

United States Health Care Official Website Stock

Is OPKO Health, Inc. a good investment? OPKO Health, Inc. (OPK) is currently trading at 1.13 USD. Market analysts have a consensus price target of 3.76 USD. This suggests a potential upside from current levels.

Earnings Schedule: OPKO Health, Inc. is expected to release its next earnings report on July 30, 2026. The market consensus estimate for Forward EPS is -0.32.

Investor FAQ

Does OPKO Health, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is OPKO Health, Inc.?

OPKO Health, Inc. is classified as a Stock. You can compare it against 5 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be July 30, 2026. The company currently has a trailing EPS of -0.27.

Company Profile

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.

Exchange Ticker
NMS (United States) OPK
TLV (Israel) OPK.TA
FRA (Germany) XCY.F
MEX (Mexico) OPK.MX
LSE (United Kingdom) 0KCS.L

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion